Uterine Fibroids Treatment Devices Market By Treatment Type (Minimally Invasive Procedures (Laparoscopic Myomectomy, Radiofrequency Ablation (RFA), Hysteroscopic Myomectomy), Non-Invasive Procedures (Focused Ultrasound), Surgical Procedures (Hysterectomy)); By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

The uterine fibroids treatment devices market was USD 4.8 billion in 2023 and is expected to reach USD 8.2 billion by 2030 at an average CAGR of 7.8% by the end of the projections period. Market growth is propelled by new developments in the medical field, growing consciousness of female health, and growing incidences of uterine fibroids.

 

Uterine fibroids are benign tumours of the uterus that can cause any or more of the following problems: heavy and prolonged menstrual periods, pelvic pain, or infertility. New therapies have emerged as more focused on minimally invasive approaches and noninvasive devices rather than surgical procedures. Uterine fibroids are treated using products such as radio frequency ablation systems, focused ultrasound systems and laparoscopic devices offering optimal symptom relief and better practice results.

 

Uterine Fibroids Treatment Devices Market: Transforming Women’s Healthcare with Innovative Solutions

Rising Prevalence of Uterine Fibroids: The rising prevalence of uterine fibroids, especially in women aged 30-50, also contributes to the growth of the market. Fibroids are benign neoplasms of the uterus and one of the most frequent gynecological disorders in females. The NIH reports that fibroids affect 70 to 80 percent of women by the age of 50, with African American women more likely to be affected.

 

Increasing Demand for Minimally Invasive Treatments: People are shifting towards choosing treatments that have a small impact on the body and heal easily and quickly without many complications. Techniques such as radiofrequency ablation and focused ultrasound are coming into focus due to their efficiency and pain-free procedures. A medical device was launched in the US in 2023 that developed a next-generation laparoscopic radiofrequency ablation device that is inclined to minimize thermal harm to the bordering tissues.

 

Awareness Campaigns and Early Diagnosis: Due to awareness of its symptoms, uterine fibroid has a high diagnosis rate and treatment. The governments and the healthcare industry are now pioneering healthcare crusades on women's health. Example: Since its launch in 2023, the European Union has championed a fibroid awareness campaign that seeks to educate women to seek medical tests for early identification of the disorder.

 

Uterine Fibroids Treatment Devices Market: Emerging Markets Offer Untapped Potential for Growth

Growing Adoption of Non-Invasive Technologies: Some of the less invasive procedures include focused ultrasound, which is used to treat fibroids without making surgery incisions, thus minimizing the risks. In 2023, a major player launched a targeted ultrasound system with Artificial Intelligence to provide accuracy for identifying fibroids.

 

Emerging Markets with Untapped Potential: Current future opportunities include the Asian-Pacific and Latin-American economies, which have improved access to health care, higher disposable income, and growing awareness of female reproductive diseases. The Asia Pacific region is expected to report 9.2% year-on-year growth owing to factors such as an increase in the rate of urbanization and the development of healthcare facilities.

 

Uterine Fibroids Treatment Devices Market: High Costs Limit Accessibility in Developing Regions

High Cost of Advanced Treatment Devices: Many women with breast cancer receive limited access to costly devices and costly treatment procedures, especially in developing countries. The Focused Ultrasound treatment costs between five thousand to ten thousand dollars on average, which is economically unfeasible for many patients.

 

Risk of Recurrence and Side Effects: Some treatments may cause fibroid regrowth or side effects, which discourages patients from undergoing minimally invasive surgeries. Clinical research conducted in 2023 showed that thirty percent to fifteen percent of the women who underwent minimally invasive surgeries may suffer from fibroid reoccurrence in five years.

 

Uterine Fibroids Treatment Devices Market Segmentation

By Treatment Type

• Minimally Invasive Procedures

  • Laparoscopic Myomectomy

  • Radiofrequency Ablation (RFA)

  • Hysteroscopic Myomectomy

• Non-Invasive Procedures

  • Focused Ultrasound

• Surgical Procedures

  • Hysterectomy

By End-User

• Hospitals

• Ambulatory Surgical Centers

• Specialty Clinics

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Segment Analysis

By Treatment Type

Minimally invasive procedures ruled the market with 50% of revenue share in 2023 because of the rising use of radiofrequency ablation and laparoscopic myomectomy. Example: This procedure has quickly gained acceptance for its suitability in eradicating fibroids without necessarily eradicating the uterus.

The non-invasive procedures segment is one of the fastest-growing segments during the forecast period, mainly due to the implementation of focused ultrasound technologies.

 

By End-User

The hospital segment ruled the market with 60% of revenue share because hospitals are the primary facilities that provide high-end fibroid procedures. Example: Modern healthcare establishments in North America and Europe give patients a great number of minimally invasive and non-invasive treatments.

Ambulatory surgical centers are on the rise due to more efficient service provision and reduced wait time for procedures.

 

Uterine Fibroids Treatment Devices Market: North America Retains Dominance with Advanced Healthcare Infrastructure

North America dominated the market in terms of revenue with 40% of the global market share in 2023 because of higher rates of uterine fibroids, a well-developed healthcare system, and a prevalent use of minimally invasive treatments. The United States represents more than 75% of the total North American market revenue owing to a favorable reimbursement scenario and procedures. In 2023, the FDA again approved a focused ultrasound system with Artificial Intelligence to improve the location accuracy of the fibroid.

 

Europe is the second-largest market owing to improved healthcare facilities, rising awareness among women and women’s healthcare, and the use of modern treatment equipment. European countries represented thirty cui percentages of global fibroid treatment in 2023. Example: Germany and the UK, these two countries are among the leading countries investing in research and development in gynecological procedures.

 

Asia-Pacific will be the fastest growing region with a CAGR of 9.2% during the forecast period. This is attributed to factors such as the growing cost of healthcare, enhanced women’s healthcare services, and rising knowledge of minimally invasive procedures. Example: The markets of Japan and China are essential, with key governments supporting their rural population to improve access to healthcare services.

 

Uterine Fibroids Treatment Devices Market: Strategies of Leading Players Shaping the Competitive Landscape

• Hologic, Inc.

• Insightec Ltd.

• Boston Scientific Corporation

• Karl Storz SE & Co. KG

• Olympus Corporation

• Smith & Nephew plc

• CooperSurgical, Inc.

• Medtronic plc

 

Future Outlook

The global uterine fibroids treatment devices market can also be expected to grow steadily over the forecast period due to technological advancements, enhancing awareness of women's health, and shifting towards non- and minimally-invasive treatments. New advancements would involve using assertive imaging, remote sensing, and specific patient technologies to increase precision and effectiveness.

 

By 2030, connected treatment systems capable of monitoring the treatment data in real-time and transferring them to the market are expected to target the market area. New entrants that focus on affordability and the provision of new service offerings will be central to the development of the market.

 

Overall, the uterine fibroids treatment devices market is a promising one with great opportunities for further development. Investors participating in research, regional growth, and technological improvements will be better positioned to harness this maturing market.